...Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting in San Diego. MerLion...
...TOC visit 17 days after the start of treatment vs. ciprofloxacin (see BioCentury Jan. 19). MerLion Pharmaceuticals Pte. Ltd....

...Agents and Chemotherapy and International Congress of Chemotherapy and Infection joint meeting in San Diego. MerLion...
...TOC visit 17 days after the start of treatment vs. ciprofloxacin (see BioCentury Jan. 19). MerLion Pharmaceuticals Pte. Ltd....

...Staphylococcus aureus. Xtoro is a pH-activated fluoroquinolone antibiotic. Alcon has exclusive, North American rights from MerLion...
...to develop and commercialize topical finafloxacin to treat ear infections (see BioCentury, Jan. 17, 2011). MerLion Pharmaceuticals Pte. Ltd....

...oral finafloxacin for the remainder of the 5- or 10-day treatment period. In 12-18 months, MerLion...
...plans to start a Phase III trial evaluating finafloxacin under the same IV-to-oral treatment protocol. MerLion Pharmaceuticals Pte. Ltd....

...oral finafloxacin for the remainder of the 5- or 10-day treatment period. In 12-18 months, MerLion...
...plans to start a Phase III trial evaluating finafloxacin under the same IV-to-oral treatment protocol. MerLion Pharmaceuticals Pte. Ltd....

...Inc. (NYSE:MRK) Belsomra suvorexant Insomnia U.S. Merck & Co. Inc. (NYSE:MRK) Keytruda pembrolizumab Melanoma U.S. MerLion Pharmaceuticals Pte. Ltd./Novartis...

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) has exclusive, North American rights from MerLion...
...topical formulation has completed a pair of Phase III trials to treat acute otitis externa. MerLion Pharmaceuticals Pte. Ltd....

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) received exclusive, North American rights from MerLion...
...to treat acute otitis externa. Novartis acquired Alcon in 2011 (see BioCentury, April 18, 2011). MerLion Pharmaceuticals Pte. Ltd....

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) received exclusive, North American rights from MerLion...
...see BioCentury, Jan. 17, 2011). Novartis acquired Alcon last year (see BioCentury, April 18, 2011). MerLion Pharmaceuticals Pte. Ltd....

...ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) received exclusive, North American rights from MerLion...
...see BioCentury, Jan. 17, 2011). Novartis acquired Alcon last year (see BioCentury, April 18, 2011). MerLion Pharmaceuticals Pte. Ltd....